FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to medical biotechnology, namely to antigen-based immunotherapy, particularly to cancer immunotherapy. Disclosed is an antigenic peptide for treating a B-cell malignant tumour, consisting of an amino acid sequence presented in SEQ ID NO 65; immunogenic compound for treating a B-cell malignant tumour containing said antigenic peptide. Disclosed is an antigen-presenting cell for treating a B-cell malignant tumour, where antigen-presenting cell is loaded with said antigen peptide or immunogenic compound; nucleic acid coding an antigenic peptide, an immunogenic compound, where the immunogenic compound is a peptide or protein. Disclosed are a pharmaceutical composition and a combination for treating a B-cell malignant tumour; use of the antigenic peptide for treating a B-cell malignant tumour; method of treating a B-cell malignant tumour in a subject in need thereof, and a multimer peptide-MHC (pMHC) for detecting antigen-specific T-cells.
EFFECT: disclosed antigenic peptide can be used to induce a specific immune response against known tumor antigens.
20 cl, 25 dwg, 7 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES AND THEIR APPLICATIONS | 2022 |
|
RU2821577C2 |
| PROPERDIN ANTIBODIES AND PRODUCTION THEREOF | 2021 |
|
RU2830308C1 |
| CHIMERIC CYTOKINE RECEPTORS CARRYING PD-1 ECTODOMAIN | 2020 |
|
RU2828214C2 |
| MUS MUSCULUS 5B9 HYBRID CULTIVATED ANIMAL CELLS- A PRODUCER OF MOUSE MONOCLONAL ANTIBODY 5B9, MONOCLONAL MOUSE ANTIBODY 5B9 AND RECOMBINANT CHIMERIC (MOUSE-HUMAN) ANTIBODY XI5B9, NEUTRALIZING RICIN RICINUS COMMUNIS | 2022 |
|
RU2802436C1 |
| MICROORGANISM HAVING DNA-BINDING TRANSCRIPTION REGULATOR OF LACI FAMILY WITH WEAKENED ACTIVITY, AND METHOD FOR PRODUCING L-GLUTAMIC ACID USING IT | 2022 |
|
RU2833333C2 |
| BCMA-SPECIFIC CHIMERIC ANTIGEN RECEPTORS CONTAINING IL-6 SIGNALLING BLOCKER | 2023 |
|
RU2828294C1 |
| MONOCLONAL ANTIBODIES AGAINST THE RECEPTOR-BINDING DOMAIN OF SARS-COV-2 SPIKE PROTEIN AND THEIR ANTIGEN-BINDING FRAGMENTS ENCODING THEIR NUCLEIC ACIDS, AS WELL AS METHODS OF THEIR USE | 2021 |
|
RU2800649C2 |
| N-GALLATES OF SYNTHETIC PEPTIDES WITH ANTIOXIDANT ACTIVITY | 2023 |
|
RU2828796C1 |
| SORAFENIB-BASED COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA | 2022 |
|
RU2800071C1 |
| METHOD FOR SPOLIGOTYPING OF MYCOBACTERIUM TUBERCULOSIS COMPLEX USING DNA AMPLIFICATION IN IMMOBILIZED PHASE AND BIOLOGICAL MICROCHIP FOR ITS IMPLEMENTATION | 2023 |
|
RU2807998C1 |
